Search clinical trials for: Fixed-Combination Drug Product (FCDP) of saxagliptin / dapagliflozin / metformin extended-release (X

Total 454052 results

AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Esperion Therapeutics, Inc.

Completed

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Healthy Lactating Women

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); A... and other collaborators

Recruiting

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Diabetes Mellitus, Type 2 | Impaired Glucose Tolerance (IGT) | Impaired Fasting Glucose (IFG)

United States
Zhujiang Hospital
Third Affiliated Hospital, Sun Yat-Sen University; Peking University Shenzhen... and other collaborators

Completed

Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy

Type 2 Diabetes Mellitus

China
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
AstraZeneca

Completed

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes

United States, United Kingdom, Germany, Hungary, Mexico, Poland, Russian Federation, Romania, Czechia, Sweden
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
AstraZeneca

Completed

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Type 2 Diabetes

United States, Hungary, Mexico, South Africa, Romania, Poland
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
AstraZeneca

Completed

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Puerto Rico, Mexico, Russian Federation, Romania, Poland, Czech Republic, United Kingdom
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation, Romania, Poland, Czech Republic, Puerto Rico, Hungary
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Incretin-based Drugs and Pancreatic Cancer

Diabetes Mellitus, Type 2

Canada
HighTide Biopharma Pty Ltd
Shenzhen HighTide Biopharmaceutical Ltd.

Recruiting

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

T2DM (Type 2 Diabetes Mellitus)

China
Beni-Suef University

Not yet recruiting

Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Polycystic Ovary

Egypt
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Eli Lilly and Company

Recruiting

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)

Type 2 Diabetes

Taiwan, United States, China, Mexico, Germany, Poland
Institute of Liver and Biliary Sciences, India

Not yet recruiting

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Decompensated Cirrhosis | Compensated Cirrhosis

India
University of Basrah

Recruiting

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

Type2diabetes

Iraq
Oman Ministry of Health

Not yet recruiting

The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes (DAPA-ANDO)

Obesity | Weight Loss | Effect of Drug | Dapagliflozin Adverse Reaction
George Medicines PTY Limited
The George Institute; Brandon Biocatalyst

Not yet recruiting

Polypill Versus Metformin in New Onset Type 2 Diabetes (PiVOT)

Type 2 Diabetes
Dong-A ST Co., Ltd.

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Diabetes Mellitus

Korea, Republic of
Beni-Suef University

Recruiting

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

PCO

Egypt
Nanjing First Hospital, Nanjing Medical University

Not yet recruiting

Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes

Insulin Resistance | Type2diabetes
Tan Tock Seng Hospital

Recruiting

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes (DMVascular)

Diabetes

Singapore
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
The George Institute
Monash University; University of Sydney; The University of New South Wales

Recruiting

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes (START)

Type 2 Diabetes

Australia
Jeil Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.

Type2 Diabetes
Newsoara Biopharma Co., Ltd.

Recruiting

Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

T2DM

China
Jeil Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
University of Guadalajara

Recruiting

Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Obesity

Mexico
AstraZeneca

Completed

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

Diabetes Mellitus, Type 2

United States, Thailand, United Kingdom, Malaysia, New Zealand, Taiwan, Turkey, Canada, Mexico, Israel, India, Argentina, Brazil, Russian Federation, Australia, Korea, Republic of, Italy, Philippines, Colombia, Poland, Chile, Finland and more
AstraZeneca

Completed

QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

Type 2 Diabetes Mellitus

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Active, not recruiting

The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease

China
Weill Cornell Medical College in Qatar
University of Hull; Hamad Medical Corporation; Sidra Medical and Research Center

Active, not recruiting

HbA1c Variability in Type II Diabetes

Diabetes Mellitus Type 2

Qatar
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4)

Breast Cancer

Malaysia, United States
The University of Texas Health Science Center at...
AstraZeneca

Completed

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration (Hyper)

Diabetes Mellitus, Type 2

United States
Uppsala University
Uppsala University Hospital; Swedish Healthcare Regions; Swedish National Board... and other collaborators

Active, not recruiting

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes (SMARTEST)

Type 2 Diabetes

Sweden
Celltrion Pharm, Inc.

Active, not recruiting

A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (EPIDOTE)

Diabetes Mellitus, Type 2

Korea, Republic of
Cook County Health
Bristol-Myers Squibb

Completed

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Hyperglycemia | Diabetes Mellitus Type 2

United States
Sabyasachi Sen

Terminated

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
AstraZeneca

Completed

To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

India

3

Subscribe